Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773279 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
A Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
- 20
- Study locations
NCT00773279: Completed Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
NCT00773279 is a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 242 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00773279, a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered by a insulin pen PDS290 (FlexTouch®) versus a Novo Nordisk marketed insulin pen (FlexPen®) in subjects with type 1 or type 2 diabetes mellitus. Furthermore, the subject's preference of the devices will be investigated by the use of questionnaires.
Conditions Studied
Interventions
- DEVICE FlexTouch®
- DEVICE FlexPen®
Study Locations (20)
California
- Novo Nordisk Investigational Site - Burlingame
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Encino
- Novo Nordisk Investigational Site - Escondido
- Novo Nordisk Investigational Site - Fresno
- Novo Nordisk Investigational Site - Mission Viejo
- Novo Nordisk Investigational Site - Orange
- Novo Nordisk Investigational Site - Poway
- Novo Nordisk Investigational Site - Salinas
- Novo Nordisk Investigational Site - Santa Monica
- Novo Nordisk Investigational Site - Tustin
- Novo Nordisk Investigational Site - Walnut Creek
Florida
- Novo Nordisk Investigational Site - Boca Raton
- Novo Nordisk Investigational Site - Hollywood
- Novo Nordisk Investigational Site - Maitland
- Novo Nordisk Investigational Site - Miami
- Novo Nordisk Investigational Site - Miami
Colorado
- Novo Nordisk Investigational Site - Aurora
- Novo Nordisk Investigational Site - Colorado Springs
- Novo Nordisk Investigational Site - Golden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00773279 record still lists
NCT00773279 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which FlexTouch® is the first listed.
NCT00773279 names 20 study sites across 3 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00773279 about?
NCT00773279 is a clinical study titled "Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics". This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered by a insulin pen PDS290 (FlexTouch®) versus a Novo Nordisk marketed ins...
What is the current status of trial NCT00773279?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2008-09. Estimated completion is 2009-06.
What conditions does trial NCT00773279 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes, Diabetes Mellitus, Type 1, Delivery Systems.
What interventions are being tested in trial NCT00773279?
The interventions under investigation include: FlexTouch® (DEVICE), FlexPen® (DEVICE).
Who is sponsoring clinical trial NCT00773279?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00773279 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00773279's enrollment target sits among peer trials
242 140th of 348 higher than 209 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia